Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139571 | 0.85 | MEN1 (0.45) | KMT2AMEN1LMNAPOLBTSHR | |
| SCHEMBL6468977 | 0.82 | MEN1 (0.41) | KMT2AMEN1LMNAPOLB | |
| SCHEMBL25176578 | 0.82 | KMT2A (0.44) | KMT2AMEN1LMNAPOLBTSHR | |
| SCHEMBL13054012 | 0.81 | MEN1 (0.33) | KMT2AMEN1RAB9ANPC1L3MBTL1 | |
| SCHEMBL186143 | 0.81 | MEN1 (0.36) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL12064263 | 0.80 | MEN1 (0.35) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL8003850 | 0.80 | MEN1 (0.48) | KMT2AMEN1LMNAPOLBTSHR | |
| SCHEMBL374442 | 0.79 | KMT2A (0.44) | KMT2AMEN1LMNAPOLBALDH1A1 | |
| SCHEMBL6468901 | 0.78 | MEN1 (0.39) | KMT2AMEN1LMNAPOLB | |
| SCHEMBL1263510 | 0.78 | MEN1 (0.50) | KMT2AMEN1LMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338141-A1 | HIV INTEGRASE INHIBITORS | ISAACS RICHARD C (US) | 2013-12-19 | — | — | US | disclosed |
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2349276-A2 | HIV INTEGRASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010042392-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042391-A2 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338141-A1 | HIV INTEGRASE INHIBITORS | POLB, CCNB1, POLR2A | KMT2A 1215/4885MEN1 3763/4885LMNA 815/4885 |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | POLB, CCNB1, POLR2A | KMT2A 1215/4885MEN1 3763/4885LMNA 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.